Sanofi Drug Beats AbbVie's Blockbuster Humira in Human Trial
- Sarilumab tested in head-to-head trial with AbbVie's Humira
- U.S. regulators set to decide on sarilumab in fourth quarter
This article is for subscribers only.
Sanofi and Regeneron Pharmaceuticals Inc. said an experimental rheumatoid arthritis therapy helped patients more than AbbVie Inc.’s Humira in a late-stage trial.
The treatment, sarilumab, improved signs and symptoms of rheumatoid arthritis more than Humira did after 24 weeks of treatment in the study, the companies said in a statement Friday. Sarilumab, a monoclonal antibody that reduces joint swelling and inflammation by blocking a protein known as IL-6, was injected every two weeks.